Tagged: cancer

$47.7 million raised so far by Atterocor via private placement


XDATA – January 4th 2016
Atterocor disclosed selling 67% of its $70.7 million brokered equity offering to twenty-one investors. The sale started on December 18th according to the document filed at the SEC. $23.01 million in additional funding can be raised before December 2016 based on the placement’s structure. The private placement’s expected net proceeds will amount to $70.2 million excluding $500,000 paid in brokerage fees by the company. Two previous unregistered financing rounds raised an estimated $17.13 million.
The company is focused on the accelerated development of a novel treatment for adrenal cancer, a rare endocrine cancer. Investors include Osage Partners, Frazier Healthcare and 5AM Ventures, The Regents of the University of Michigan through its “MINTS” program, and The Michigan Pre-Seed Capital Fund.
The company, headquartered in Ann Arbor MI, is led by Julia C Owens (President and CEO). Atterocor elected to keep its revenues undisclosed.
The board of directors includes Carol Gallagher, James Topper, Randall Whitcomb and William Harrington.

The company has raised an estimated total of $64.83 million via private unregistered security offerings.

Offering recap
Status: First close
Company: Atterocor
Industry: Pharmaceuticals
Amount offered: $70.7 million
Amount placed: $47.7 million
SEC filing: Source
First sale: 12-18-2015
Data as of: 01-04-2016

Arvinas Holding Company completed a new $41.61 million equity offering


XDATA – October 23rd 2015
Arvinas Holding Company issued equity for a total of $41.61 million in a non-brokered investment round. The transaction which started a week ago, garnered the support of sixteen investors. No offering was previously initiated by the company under a registration exemption with the SEC.
Arvinas Holding Company develops novel therapeutics to treat a variety of diseases including cancer, pro-inflammatory, autoimmune and rare diseases. Central to the company’s proprietary approach is the targeting of disease-causing proteins for degradation thus eliminating them from the body. The company is backed by Merck.
The company was registered in 2014 and has its headquarters located in New Haven CT. Arvinas Holding Company elected to keep its revenues undisclosed.
The executive team includes Manuel Litchman and Sean Cassidy.
The board of directors includes Andrew Levin, Brad Margus, Jonathan Soderstrom, Kush Parmar, Liam Ratcliffe, Stephen Squinto and Tim Shannon.
Offering recap
Status: Completed
Company: Arvinas Holding Company
Industry: Biotechnology
Amount offered: $41.61 million
Amount placed: $41.61 million
SEC filing: Source
First sale: 10-16-2015
Data as of: 10-23-2015

 

Hey if you didn’t know about it, maybe it is time to add XDATA as part of your market monitoring regimen.

For more information visit www.XDATA.co

$71 million pre-IPO financing round completed by Conkwest


conkwestHey if you didn’t know about it, maybe it is time to add XDATA as part of your market monitoring regimen, 14 days free trials are available here.

A $71 million unregistered equity financing by Conkwest successfully drew to a close. The non-brokered investment round was placed among nine investors. The subscription started almost two weeks ago. A total of five unregistered securities offerings closed by the company raised an estimated $69.17 million.
Conkwest develops and commercializes a product pipeline for the treatment of cancers and viral infections. The company’s products are based on the proprietary cancer-killing cell line Neukoplast (also known as NK-92) – the only cell line that can be commercialized as a direct, scalable, off-the-shelf cancer-killing product. The company is backed by Dr. Patrick Soon-Shiong and Sorrento Therapeutics.
The company is headquartered in Cardiff-by-the-sea CA. Conkwest elected to keep its revenues undisclosed.
The executive team includes Barry J Simon, Patrick Soon-Shiong and Richard Gomberg.
The board of directors includes Hans Klingemann, Henry Ji, John C Thomas, John T Potts, Richard Kusserow, Robert Rosen and Steve Gorlin.The company has raised an estimated total of $140.17 million via private unregistered security offerings.
Offering recap
Status: Completed
Company: Conkwest
Industry: Biotechnology
Amount offered: $71 million
Amount placed: $71 million
SEC filing: Source
First sale: 06-10-2015
Data as of: 06-22-2015

For more information visit www.XDATA.co

Syros Pharmaceuticals completed a new $53 million equity offering


syros Syros Pharmaceuticals sold a total of $53.15 million in a non-brokered equity investment round. The transaction which started on October 9th, garnered the support of sixteen investors. Two previous unregistered financing rounds raised an estimated $13.25 million.

Syros Pharmaceuticals develops a proprietary platform that identifies the master switches for disease genes, opening a new approach to novel therapeutics. The company’s initial focus is on cancer, but the platform will also be applicable to other therapeutic areas. Investors include ARCH Venture Partners and Flagship Ventures.

The company, headquartered in Watertown MA, is led by Nancy Simonian (CEO). Syros Pharmaceuticals elected to keep its revenues undisclosed.
The executive team includes Jorge Conde.
The board of directors includes Douglas Cole, James E Bradner, Philip Sharp, Richard A Young, Robert Nelsen, Stephane Bancel and Vicki Sato.

The company has raised an estimated total of $66.4 million via private unregistered security offerings.

Offering recap
Status: Completed
Company: Syros Pharmaceuticals
Industry: Biotechnology
Amount offered: $53.15 million
Amount placed: $53.15 million
First sale: 10-09-2014
Data as of: 10-24-2014

For more information visit www.XDATA.co

Eureka Therapeutics reported the completion of a $21 million financing round


XDATA – September 22nd 2014

eurica therapeutics $21 million was raised by Eureka Therapeutics following the successful placement and issuance of its unregistered equity securities. A total of twenty-eight investors participated to the non-brokered placement which started one month ago. No offering was previously initiated by the company under a registration exemption with the SEC.

The company is engaged in the discovery of novel antibody immunotherapies. The company utilizes a paradigm-changing technology platform to develop fully-human antibodies against intracellular cancer antigens.

The company, headquartered in Emeryville CA, is led by Cheng Liu (President). Eureka Therapeutics elected to keep its revenues undisclosed.
The board of directors includes Chih-kai Cheng, Hsing Kung, Qiushi Fu and Sandy Chau.

Offering recap
Status: Completed
Company: Eureka Therapeutics
Industry: Biotechnology
Amount offered: $21 million
Amount placed: $21 million
First sale: 08-20-2014
Data as of: 08-20-2014

For more information visit www.XDATA.co

Nanospectra Biosciences completed a new equity offering


XDATA – August 29th 2014

nanospecta Nanospectra Biosciences sold a total of $800,000 in a non-brokered equity investment round. The transaction which started a week ago, garnered the support of fifteen investors. A total of six unregistered securities offerings closed by the company raised an estimated $7.9 million.

The company is focused on the development of AuroLase therapy utilizing AuroShell Particles (also referred to as nanoshells) for the precise, particle-based thermal ablation of solid tumors. The AuroLase therapy process involves infusing a single dose of nanoshell particles into the patient’s blood stream via intravenous injection. After 12 to 24 hours, enough time for the particles to accumulate inside the tumor, a special laser is used to illuminate and heat the particles within the tumor.

The company, headquartered in Houston TX, is led by David Jorden (CEO). Nanospectra Biosciences elected to keep its revenues undisclosed.
The executive team includes Glenn Goodrich and Patrick Pace.
The board of directors includes Bradley Nyberg, David Bristol and Jennifer West.

The company has raised an estimated total of $8.7 million via private unregistered security offerings.

Offering recap
Status: Completed
Company: Nanospectra Biosciences
Industry: Other Health Care
Amount offered: $800,000
Amount placed: $800,000
First sale: 08-22-2014
Data as of: 08-29-2014

For more information visit www.XDATA.co

Tosk closed its equity security offering after increasing its fundraising cap


Change: offered +7% / raised +230% / placed 100%

XDATA – August 22nd 2014

toskTosk closed its unregistered equity offering after increasing the placement’s size by 7% to $5.45 million. The offer closed after the company raised $3.8 million from sixty-two additional investors within a little over a year. At closing, a total of seventy-four investors had subscribed to Tosk‘s offering. The company closed two unregistered private placements which raised an estimated $7 million.

Tosk develops drugs for debilitating and life-threatening diseases such as cancer, arthritis, and psoriasis. The company’s current drug discovery and development efforts focus on applying the optimizing market drug (OMD) technology to discover cancer chemotherapeutic side-effect-reducing agents.

The company, headquartered in Mountain View CA, is led by Brian Frenzel (President and CEO). Revenues on or below $1 million were reported by Tosk.
The board of directors includes Charles Garvin and Harold Crow.

The company has raised an estimated total of $12.45 million via private unregistered security offerings.

Offering recap
Status: Completed
Company: Tosk
Industry: Pharmaceuticals
Amount offered: $5.45 million
Amount placed: $5.45 million
First sale: 12-16-2011
Data as of: 08-22-2014

For more information visit www.XDATA.co

$215,000 raised by MetaStat as part of its mezzanine investment round


metastatMetaStat disclosed selling 36% of its non-brokered mezzanine financing. The company launched a $600,000 investment round subscribed so far by six investors. The subscription which raised $215,000 started one month ago. The offering will remain open until May 2015 while an additional $385,000 worth of securities is sold to investors. A total of five unregistered securities offerings closed by the company raised an estimated $15 million.
MetaStat trades under symbol OTC: MTST
The company is a development stage life sciences organization that develops and commercializes diagnostic products and novel therapeutics for the early and prediction and treatment of systemic metastasis – cancer that spreads from a primary tumor through the bloodstream to other areas of the body.
The company is headquartered in Montclair NJ. MetaStat kept its revenues undisclosed.
The executive team includes Daniel Schneiderman, Oscar Bronsther and Warren Lau.
The board of directors includes David Epstein, David Siegel, Johan (thijs) Spoor and Patrick Mooney.The company has raised an estimated total of $15.22 million via private unregistered security offerings.
Offering recap
Status: First close
Company: MetaStat
Industry: Biotechnology
Amount offered: $600,000
Amount placed: $215,000
First sale: 05-22-2014
Data as of: 06-20-2014

For more information visit www.XDATA.co

Sabik Medical re-opened its offering to place $257,000 more


Change: offered +30% / raised +30% / placed 100%

Sabik Medical re-opened and closed its unregistered equity offering after increasing the placement’s size from $858,000 to $1.11 million. The offer closed after the company raised $257,000 from six additional investors within six months. At closing, a total of twenty-nine investors had subscribed to Sabik Medical’s offering. The offering’s expected net proceeds amount to $1.01 million, excluding $100,000 earmarked for the payment of officers’ salaries. This was the first offering under regulation D filed by Sabik Medical.

Sabik Medical develops and commercializes a radiopharmaceutical compound to diagnose, stage and treat cancer with an initial focus on prostate cancer. The compound known as Enzyme Mediated Imaging and Therapy (EMIT) acts as a ‘shuttle’ that selectively deposits radioisotopes of iodine at the site of the tumor.

The company, headquartered in Sudbury MA, is led by James Jenson (President and CEO). Sabik Medical kept its revenues undisclosed.
The executive team includes Allan Green.
The board of directors includes Daniel L Peters, Howard Fillit and Stephen Sands.

Offering recap
Status: Completed
Company: Sabik Medical
Industry: Biotechnology
Amount offered: $1.11 million
Amount placed: $1.11 million
First sale: 10-23-2013
Data as of: 05-20-2014

Immunome revised its offering cap upward to $800,000 and received $735,000 in commitments


Change: offered +33% / raised +268% / placed 92%

immunomeImmunome upped its financing to $800,000 from $600,000 after receiving new commitments. A total of twenty-two additional backers invested $535,000 in the company’s offering. The prior information, filed on March 3rd, stated one investor had committed $200,000. Immunome’s offering has $65,000 left up for subscription. The offering’s expected net proceeds amount to $720,000, excluding $80,000 earmarked for the payment of officers’ salaries. The subscription is structured to close once the 8% left is fully subscribed or in almost a year at the latest. The company closed four unregistered private placements which raised an estimated $3.88 million. The company is backed by BioAdvance Greenhouse Fund which provides seed and pre-seed capital for companies developing new technologies to improve human health.

The company works toward creating new, safe, and powerful cancer therapies by targeting stem cell and universal cancer antigens. New targets are needed to create antibody drugs with better activity against diverse tumor types, less resistance, fewer off-target effects, and superior survival outcomes.

The company is headquartered in Wynnewood PA. Immunome kept its revenues undisclosed.
The executive team includes Jane H Hollingsworth, Joan Lau, Joel H Sussman and Scott K Dessain.
The board of directors includes Gregory Harriman, I Wistar Morris and Michael D Widlitz.

The company has raised an estimated total of $4.62 million via private unregistered security offerings.

Offering recap
Status: Intermediary close
Company: Immunome
Industry: Pharmaceuticals
Amount offered: $800,000
Amount placed: $735,000
First sale: 02-19-2014
Data as of: 03-19-2014